Intrexon CorpNYSE
Advanced Chart
  • Aug. 12, 2015, 7:49 AM
    • Intrexon (NYSE:XON) acquires UK-based Oxitec Limited for $80M in cash and $80M in XON common stock.
    • Oxitec is a pioneer in using advanced genetics and molecular biology to control insect populations via the production of sterile, self-limiting insects whose offspring do not survive. Its main focus is controlling disease-propagating mosquitoes and pest-related crop damage.
    • The transaction is expected to close later this year.
    | Aug. 12, 2015, 7:49 AM | 2 Comments
  • Feb. 13, 2015, 8:29 AM
    • Intrexon (NYSE:XON) acquires ActoGenix, a Belgian clinical stage biopharma company that is developing a class of products called ActoBiotics, based on the molecular engineering of food-grade microbes (Lactococcus lactis).
    • ActoBiotics combine the selectivity and low toxicity of protein-based biopharmaceuticals with the added benefits of oral availability and cost-effective formulation and manufacturing. Its lead product candidates are AG013, a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab (antibody) to treat inflammatory bowel disease.
    • Under the terms of the acquisition agreement, Intrexon will pay $30M in cash and $30M in Intrexon stock. The transaction is expected to close this quarter.
    | Feb. 13, 2015, 8:29 AM | 1 Comment
  • Jan. 26, 2015, 12:30 PM
    • Synthetic biology leader Intrexon (XON +2.9%) acquires the remaining stake in Exemplar Genetics, a developer of a broad line of transgenic swine models used in the research and development of a variety of diseases. Financial terms are undisclosed.
    | Jan. 26, 2015, 12:30 PM
  • Jul. 2, 2014, 11:07 AM
    • Intrexon (XON +2.5%) enters into a definitive agreement to acquire Trans Ova Genetics, a provider of genetic cattle breeding services. The acquisition will broaden XON's reach in animal health and productivity.
    • Under the terms of the agreement, Trans Ova shareholders will receive $60M in upfront cash, $30M in XON common stock and deferred payments of up to $20M. Trans Ova delivered net income of $~4.9M on revenues of $63.3M in 2013.
    • Intrexon expects the transaction to close in Q3.
    | Jul. 2, 2014, 11:07 AM
  • Mar. 7, 2014, 9:06 AM
    • Intrexon (XON) finalizes its buy of Medistem, a developer of endometrial regenerative cells (ERC). The company believes that ERCs can potentially be manufactured as genetically modified therapeutics delivery vehicles in the body.
    • 116 mutual funds have positions in the stock.
    | Mar. 7, 2014, 9:06 AM
  • Dec. 20, 2013, 3:55 PM
    • Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
    • XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
    • More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
    • MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
    | Dec. 20, 2013, 3:55 PM